Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.79 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.77 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3517769 | 0.98 | ALDH1A1 (0.77) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL407477 | 0.89 | ALDH1A1 (1.00) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL11177620 | 0.88 | TDP1 (1.00) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL5187812 | 0.88 | TDP1 (0.67) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL2916059 | 0.88 | PRMT1 (0.71) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL10460741 | 0.88 | ALDH1A1 (0.69) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL13073499 | 0.88 | TAAR1 (1.00) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL14156120 | 0.88 | ALDH1A1 (0.84) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 | |
| SCHEMBL625181 | 0.88 | ALDH1A1 (0.84) | ALDH1A1PRMT1TAAR1HSD17B10CA1 | |
| SCHEMBL10460354 | 0.88 | ALDH1A1 (0.70) | ALDH1A1PRMT1TAAR1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107405318-A | For treating the compound of the patient's condition related to nadph oxidase | 格卢科克斯生物科技有限公司 | 2017-11-28 | — | — | CN | claimed |
| CN-103588697-B | Disubstituted benzenes sulfamide compound of one class 2,5 and its production and use | 中国科学院上海药物研究所 | 2017-09-15 | — | — | CN | claimed |
| US-20030216451-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| CN-106146362-B | Method for synthesizing C-7280948 | 南京理工大学 | 2018-04-03 | — | — | CN | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| CN-107405318-A | For treating the compound of the patient's condition related to nadph oxidase | 格卢科克斯生物科技有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-103588697-B | Disubstituted benzenes sulfamide compound of one class 2,5 and its production and use | 中国科学院上海药物研究所 | 2017-09-15 | — | — | CN | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1633732-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004101544-A1 | BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0194548-A2 | Sulfonylaminoethyl compounds, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1986-09-17 | — | — | EP | disclosed |
| US-4443477-A | ANTICOAGULANTS, ANTILIPEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-04-17 | — | — | US | disclosed |
| EP-0031954-B1 | SULPHONAMIDES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1984-03-14 | — | — | EP | disclosed |
| EP-0031954-A2 | Sulphonamides, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885PRMT1 254/4885TAAR1 3372/4885 |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | ALDH1A1 1694/4885PRMT1 111/4885TAAR1 2496/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885PRMT1 254/4885TAAR1 3372/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ALDH1A1 2072/4885PRMT1 254/4885TAAR1 3372/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ALDH1A1 2072/4885PRMT1 254/4885TAAR1 3372/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | ALDH1A1 2578/4885PRMT1 516/4885TAAR1 3753/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885PRMT1 254/4885TAAR1 3372/4885 |
| US-20030216451-A1 | Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, F2 | ALDH1A1 3342/4885PRMT1 3494/4885TAAR1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.